Polycystic Kidney Disease Drugs Market Segmentation:
Type {Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD)}
The global polycystic kidney disease drugs market is segmented and analyzed for demand and supply by type into autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and others. Out of the three types of segments, the autosomal dominant polycystic kidney disease (ADPKD) segment is anticipated to capture the largest market size in the global polycystic kidney disease drugs market over the projected time frame. The growth of the segment can be attributed to the worldwide increasing incidence of autosomal dominant polycystic kidney diseases. For instance, it was observed that the prevalence of ADPKD is estimated to be somewhere between 1 in 500-1,000 among the general population. Each year, about 5,900 new cases are recorded in the United States. Besides this, escalating approval of the novel drugs is also anticipated to propel the segment growth over the projected time frame.
End-user (Hospitals, Specialty Clinics)
The global polycystic kidney disease drugs market is also segmented and analyzed for demand and supply by the end user into hospitals, specialty clinics, and others. Amongst these three segments, the hospitals segment is expected to garner a significant share owing to the fact that patients suffering from polycystic kidney disease often visit hospitals for treatments such as hemodialysis and peritoneal dialysis. Therefore, an increase in the PKD patient pool is anticipated to fuel the segment growth, along with the adequacy of favorable reimbursement policies in developed nations, is estimated to drive the growth of the segment over the forecast period. On the other hand, the specialty clinics segment is projected to witness a notable CAGR during the forecast period, owing to the rising awareness of this disease amongst people across the globe. The growing inclination of patients towards early diagnosis and treatment of polycystic kidney disease is also propelling the demand for quality treatment. This, as a result, is projected to generate numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By Diagnosis |
|
|
By End User |
|
